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Background: Venous thromboembolism (VTE) prophylaxis remains underutilized, particularly in cancer patients. We
explored clinical predictors of prophylaxis in hospitalized cancer patients before the onset of acute VTE.
Methods: In the SWiss Venous ThromboEmbolism Registry, 257 cancer patients (616 15 years) with acute VTE and
prior hospitalization for acute medical illness or surgery within 30 days (91% were at high risk with Geneva VTE risk
score ‡3) were enrolled.
Results: Overall, 153 (60%) patients received prophylaxis (49% pharmacological and 21% mechanical) before the
onset of acute VTE. Outpatient status at the time of VTE diagnosis [odds ratio (OR) 0.31, 95% confidence interval (CI)
0.18–0.53], ongoing chemotherapy (OR 0.51, 95% CI 0.31–0.85), and recent chemotherapy (OR 0.53, 95% CI 0.32–
0.88) were univariately associated with the absence of VTE prophylaxis. In multivariate analysis, intensive care unit
admission within 30 days (OR 7.02, 95% CI 2.38–20.64), prior deep vein thrombosis (OR 3.48, 95% CI 2.14–5.64),
surgery within 30 days (OR 2.43, 95% CI 1.19–4.99), bed rest >3 days (OR 2.02, 95% CI 1.08–3.78), and outpatient
status (OR 0.38, 95% CI 0.19–0.76) remained the only independent predictors of thromboprophylaxis.
Conclusions: Although most hospitalized cancer patients were at high risk, 40% did not receive any prophylaxis
before the onset of acute VTE. There is a need to improve thromboprophylaxis in cancer patients, particularly in the
presence of recent or ongoing chemotherapy.
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introduction
Patients with cancer have a sixfold increased risk of venous
thromboembolism (VTE) compared with those without cancer
[1, 2]. VTE remains the second leading cause of death among
cancer patients [3] and the first leading cause of death in
patients with cancer receiving outpatient chemotherapy [4]. In
autopsy studies, the rate of deep vein thrombosis (DVT) or
pulmonary embolism (PE) among cancer patients
approximates 50% [5]. Moreover, VTE is a significant predictor
of mortality in cancer patients [6–8].
Added to cancer-related mechanisms, cancer therapy,
including administration of prothrombotic chemotherapeutic
drugs, use of central venous catheters, major surgery, and
prolonged immobilization, further increases the risk of VTE
[9, 10]. Patients with cancer undergoing surgery have a twofold
increase in the risk of VTE in comparison to patients without
cancer undergoing similar procedures [11, 12], and the risk
persists beyond hospital discharge [13–15]. Moreover, the risk
of VTE is doubled in patients with metastatic disease or those
undergoing chemotherapy, compared with patients with
localized cancer or patients without chemotherapy [16].
Several randomized controlled trials confirmed that
thromboprophylaxis among cancer patients safely prevents VTE,
with a 45%–68% reduction in relative risk of VTE compared
with placebo [17–21]. Therefore, current consensus guidelines
of the American College of Chest Physicians [22] and the
American Society of Clinical Oncology [23] recommend
prophylaxis in acutely ill medical patients with cancer or
patients undergoing major cancer surgery (grade 1A).
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We investigated thromboprophylaxis and its predictors
before the onset of acute VTE in hospitalized cancer patients.
methods
patients
Overall, 257 consecutive cancer patients with objectively confirmed acute
DVT or PE and hospitalization within 30 days before the onset of acute
VTE in four academic and 10 nonacademic acute care hospitals in
Switzerland were enrolled in the prospective SWIss Venous
ThromboEmbolism Registry (SWIVTER) from 1 April 2006 to 31 March
2008. Inclusion criteria were age ‡18 years and hospitalization for an acute
illness within 30 days before acute VTE event (medical patients) or
hospitalization with trauma or surgery within 30 days before the onset of
acute VTE (surgical patients). The only exclusion criterion was
hospitalization for acute VTE within 30 days before the enrollment. Patients
were classified as inpatients if VTE was diagnosed during hospitalization,
and they were classified as outpatients if VTE was diagnosed within 30 days
after a hospitalization. Eligible patients were enrolled during clinical
inpatient or outpatient visits or at the time of VTE diagnosis. DVT had to
be objectively confirmed with ultrasound or phlebography and PE by
contrast-enhanced chest computed tomography, ventilation perfusion scan,
conventional pulmonary angiography, or magnetic resonance imaging. The
detailed methodology of SWIVTER has been described elsewhere [24].
data and statistical analysis
The Geneva risk score was used for an objective assessment to identify
patients at high risk for VTE [25]. According to this score,
thromboprophylaxis is indicated in patients with a score ‡3 points. Two
points are reserved for the following risk factors: cardiac failure, respiratory
failure, recent stroke, recent myocardial infarction, acute infectious disease
(including sepsis), acute rheumatic disease, cancer, myeloproliferative
syndrome, nephrotic syndrome, prior VTE, and known hypercoagulable
state; one point is reserved for the following risk factors: immobilization >3
days, recent travel >6 h, age >60 years, body mass index >30 kg/m2, chronic
venous insufficiency, pregnancy, hormonal therapy, and dehydration.
Continuous variables with a normal distribution are described as means
with standard deviations, and group comparisons were carried out with the
t-test; continuous variables with skewed distribution are presented as
median values with interquartile ranges, and group comparisons were
carried out with a rank sum test. Discrete variables are presented as
frequencies and percentages, and group comparisons were carried out using
the chi-square or Fisher’s exact test. Bonferroni’s correction for multiple
group comparisons indicated a P value <0.002 for statistical significance.
Univariate logistic regression analysis reporting odds ratios with 95%
confidence intervals was conducted to identify clinical predictors for the use
of prophylaxis within 30 days before the onset of VTE. Then, multivariate
logistic regression analysis was carried out to identify independent clinical
predictors of prophylaxis within 30 days before the onset of VTE.
Univariate predictors with a P value <0.05 were included in the regression
model; and a stepwise backward variable elimination procedure was used
for obtaining the final multivariate regression model. All reported P values
are two tailed. Data were analyzed using STATA 9 software (STATACorp
LP, College Station, TX).
results
patient characteristics
Among the 257 enrolled patients, 49% were women, and mean
age was 61 6 15 years. The median duration of hospital stay
before the onset of acute VTE was 16 days (interquartile range
8–27 days). Overall, 234 (91%) patients were at high risk
(Geneva VTE risk score ‡3), 171 (66%) had metastatic cancer,
136 (53%) were immobile for >3 days, 116 (45%) had recent
and 111 (43%) ongoing chemotherapy, 103 (40%) had surgery
within 30 days, 91 (35%) had an indwelling central line, 62
(24%) were admitted to the intensive care unit (ICU) within
30 days, 43 (17%) had prior DVT, and 27 (11%) prior PE
(Table 1). DVT alone was diagnosed in 102 (40%), acute PE in
99 (38%), and PE plus DVT in 56 (22%) patients. Among
patients with acute DVT with or without PE, 155 (70%)
had proximal, 93 (42%) distal, and 25 (11%) upper extremity
vein thrombosis. At the time of VTE diagnosis, 199 (77%)
were inpatients and 58 (23%) were outpatients. A Geneva
VTE risk score ‡3 was present in 94% of the inpatients and in
84% of the outpatients during the preceding hospitalization
(P = 0.022).
In total, 19 (7%) patients died within 7 days after VTE
diagnosis: VTE was the main cause of death in 10 (53%)
of these patients, and VTE likely contributed to death in
15 (79%).
type of VTE prophylaxis within 30 days before the
onset of VTE
Overall, 153 (60%) patients received thromboprophylaxis
before the acute index VTE; among the 144 medical patients,
69 (48%) received prophylaxis, and among the 113 surgical
or trauma patients, 84 (74%) received prophylaxis (P < 0.001).
In total, pharmacological prophylaxis was used in 125 (49%)
patients and mechanical methods in 53 (21%). Among the
patients with pharmacological prophylaxis, 92 (74%)
received low-molecular weight heparin; the median dose for
dalteparin was 5000 IU, for enoxaparin 4000 IU, and for
nadroparin 2850 IU. Unfractionated heparin was used in 21
(16%) patients, and 18 (14%) patients were on vitamin
K antagonists before the onset of VTE. Combined mechanical
plus pharmacological prophylaxis was used in 25 (10%)
patients. Among the 153 patients with prophylaxis, it was
stopped before the onset of VTE in 27 (18%) patients with
a median prophylaxis suspension time of 9 days (interquartile
range 4–14 days).
Among the 104 patients without prophylaxis, 88 (85%) had
a Geneva VTE risk score ‡3. The proportion of patients with
prophylaxis according to the Geneva VTE risk score is shown in
Figure 1. Among the 111 patients with ongoing chemotherapy,
56 (50%) received VTE prophylaxis, and among the 103
patients undergoing surgery for cancer, 79 (77%) received
prophylaxis. Thromboprophylaxis within 30 days was more
frequently used in inpatients (n = 133; 67%) than in outpatients
(n = 20; 34%) (P < 0.001).
Among the 144 medical patients, 84 (58%) had ongoing
chemotherapy and 115 (80%) metastatic cancer. There was no
difference in the rate of thromboprophylaxis between the
medical patients with and without ongoing chemotherapy
(45% versus 55%, respectively; P = 0.45). There was no
difference in the rate of thromboprophylaxis between the
medical patients with and without metastatic cancer (50%
versus 50%, respectively; P = 0.23).
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predictors of VTE prophylaxis before the onset of
acute VTE
The strongest univariate predictors of prophylaxis were ICU
admission within 30 days, surgery within 30 days, and use of an
indwelling central catheter (Table 2). Outpatient status at the
time of VTE diagnosis, ongoing chemotherapy, and recent
chemotherapy were univariately associated with the absence of
VTE prophylaxis.
In multivariate analysis, ICU admission, prior DVT, surgery
within 30 days, bed rest >3 days, and outpatient status at
the time of VTE diagnosis remained the only clinical
factors that independently predicted the use of prophylaxis
(Table 3).
discussion
The present analysis from the SWIVTER showed that only 60%
of cancer patients hospitalized for an acute medical illness or
surgery within 30 days before the index VTE event were
receiving thromboprophylaxis at the time of onset. This finding
is consistent with the results of observational studies
confirming that a large proportion of hospitalized patients do
not receive prophylaxis before the VTE event [24–26].
In our study, the prophylaxis rate before VTE in the medical
inpatients with cancer was similar (48%) to that of the
multinational International Medical Prevention Registry on
Venous Thromboembolism (IMPROVE) registry (45%) [27].
In the Spanish Registro Informatizado de la Enfermedad
Table 1. Patient demographics, chronic and acute comorbidities
Total, N = 257 Prophylaxis, n = 153 No prophylaxis, n = 104 P
Demographics
Age, years, mean 6 SD 61.5 6 15.1 61.1 6 15.3 62.2 6 14.8 0.58
Women, n (%) 127 (49.4) 75 (49.0) 52 (50.0) 0.88
Chronic comorbidities
Metastatic cancer, n (%) 171 (66.5) 100 (65.4) 71 (68.3) 0.63
Chemotherapy within 6 months, n (%) 116 (45.1) 59 (38.6) 57 (54.8) 0.013
Cancer surgery within 6 months, n (%) 77 (26.1) 49 (32.0) 28 (26.9) 0.39
Radiotherapy within 6 months, n (%) 46 (17.9) 25 (16.3) 21 (20.2) 0.44
Prior DVT, n (%) 43 (16.7) 36 (23.5) 7 (6.7) <0.001
Chronic lung disease, n (%) 33 (12.8) 23 (15.0) 10 (9.6) 0.20
Neurological disorder, n (%) 28 (10.9) 17 (11.1) 11 (10.6) 0.89
Prior PE, n (%) 27 (10.5) 22 (14.4) 5 (4.8) 0.014
Obesity, n (%) 15 (5.9) 12 (7.8) 3 (2.9) 0.096
Thrombocytopenia, n (%) 12 (4.7) 4 (2.6) 8 (7.7) 0.058
Congestive heart failure, n (%) 11 (4.3) 9 (5.9) 2 (1.9) 0.12
Renal failure, n (%) 11 (4.3) 8 (5.2) 3 (2.9) 0.36
Liver disease, n (%) 11 (4.3) 6 (2.1) 5 (4.8) 0.73
Varicous veins, n (%) 7 (2.7) 5 (3.3) 2 (1.9) 0.52
Acute comorbidities <30 days
Bed rest >3 days, n (%) 136 (52.9) 94 (61.4) 42 (40.4) 0.001
Ongoing chemotherapy, n (%) 111 (43.1) 56 (36.6) 55 (52.9) 0.010
Surgery, n (%)a 103 (40.0) 79 (76.7) 24 (23.3) <0.001
Indwelling central line, n (%) 91 (35.4) 70 (45.8) 21 (20.2) <0.001
Nonpulmonary infection, n (%) 63 (24.5) 43 (28.1) 20 (19.2) 0.11
ICU admission, n (%) 62 (24.1) 57 (37.2) 5 (4.8) <0.001
Pulmonary infection, n (%) 31 (12.1) 19 (12.4) 12 (11.5) 0.83
Bleeding, n (%) 31 (12.1) 20 (13.1) 11 (10.6) 0.55
Acute respiratory failure, n (%) 26 (10.1) 17 (11.1) 9 (8.7) 0.52
Sepsis, n (%) 21 (8.2) 14 (9.2) 7 (6.7) 0.49
Ischemic stroke or palsy, n (%) 19 (7.4) 17 (11.1) 2 (1.9) 0.006
Dehydration, n (%) 14 (5.5) 16 (4.9) 6 (5.8) 0.85
Trauma, n (%) 12 (4.7) 7 (4.6) 5 (4.8) 0.93
Acute heart failure, n (%) 10 (3.9) 7 (4.6) 3 (2.9) 0.49
Acute coronary syndrome, n (%) 3 (1.2) 3 (2.0) 0 (0.0) 0.15
Acute rheumatic disease, n (%) 3 (1.2) 2 (1.3) 1 (1.0) 0.80
Hospital days, median (IQ range) 16 (8–27) 19 (11–29) 10 (4–24) <0.001
Hospital stay >15 days, n (%) 137 (53.3) 94 (61.4) 43 (41.4) 0.002
Mortality at 7 days, n (%) 19 (7.4) 15 (9.8) 4 (3.9) 0.073
asome patients had more than one surgical procedure.
SD, standard deviation; DVT, deep vein thrombosis; PE, pulmonary embolism; ICU, intensive care unit; IQ, interquartile.
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TromboEmbolica (RIETE) registry, 24% of the medical and
71% of the surgical cancer inpatients received
thromboprophylaxis before the onset of acute VTE [28]. Of
note, SWIVTER included a higher proportion (45%) of cancer
patients than the RIETE (13%) and the IMPROVE (12%)
registries [24].
In the present study, almost one-quarter (23%) developed
VTE as outpatients shortly after a hospitalization, confirming
that cancer patients have an ongoing risk of VTE beyond the
hospital stay [13–15]. In outpatients with cancer, VTE
prophylaxis is currently not recommended by international
consensus guidelines and not reimbursed in many countries.
Not surprisingly, we found that outpatient diagnosis of VTE
independently predicted absent prophylaxis. Further studies are
required to investigate whether thromboprophylaxis should be
recommended in cancer outpatients at high risk of VTE.
The majority of our cancer population had additional VTE
risk factors, including ongoing chemotherapy, metastatic
disease, recent surgery, indwelling central venous catheter, or
a personal history of VTE. Thus, >90% of patients had an
indication for prophylaxis according to the Geneva risk score
[25]. An increased risk of bleeding before the onset of VTE may
partially explain the omission of pharmacological
thromboprophylaxis. The proportion of patients with
thrombocytopenia was rather low (5%), and not surprisingly,
we found a strong trend toward nonprescription of prophylaxis
in those patients. However, there is no reason to withhold
mechanical thromboprophylaxis in cancer patients with an
increased risk of bleeding.
In SWIVTER, we investigated clinical predictors of
thromboprophylaxis [24]. Several known VTE risk factors, such
as ICU admission, surgery within 30 days, bed rest >3 days, and
prior DVT independently predicted the use of prophylaxis. We
were surprised by the finding that none of the other important
VTE risk factors, including age, obesity, and metastatic disease,
and none of the acute comorbidities, including acute heart
failure, respiratory failure, and infections, were predictive for
prophylaxis. Additionally, the finding that both recent and
ongoing chemotherapy were associated with the absence of
prophylaxis is troublesome. In a recent study of outpatients
with chemotherapy-related VTE, the site of cancer, an increased
platelet count, a hemoglobin level of <100 g/l or use of red cell
growth factors, an increased leukocyte count, and the presence
of obesity predicted VTE [29].
Potential explanations for the observed underuse of VTE
prophylaxis in cancer patients may include an increased risk of
bleeding, use of chemotherapeutic drugs affecting angiogenesis,
presence of transient chemotherapy-induced
thrombocytopenia, reduced quality of life through daily
injections, or cost–benefit concerns. In addition, patients with
end-stage disease usually do not receive thromboprophylaxis;
however, the proportion of patients with terminal cancer was
probably not substantial in our analysis because of a low overall
in-hospital mortality rate (7%).
The strength of the present study is the prospectivemulticentric
enrollment of consecutive cancer patients who developed acute
VTE during or shortly after hospitalization with detailed
information on VTE risk factors, comorbidities, and prophylaxis
modalities. A weakness of the study is that no information on type
of cancer or type and duration of chemotherapy was collected.
Another study limitation is the use of the nonvalidated Geneva
VTE risk score. However, it is unlikely that the observed rate of
appropriate prophylaxis would have changed significantly by the
use of another risk score because the proportion of patients with
multiple VTE risk factors was substantial.
The present data—together with the findings from the RIETE
and IMPROVE registries—confirm that there is a definite need
Figure 1. Venous thromboembolism prophylaxis in cancer patients
according to the GENEVA risk score.
Table 2. Univariate clinical predictors of prophylaxis in patients with
cancer
Predictor OR 95% CI P
ICU admission 11.76 4.52–30.59 <0.001
Surgery within 30 days 3.56 2.04–6.20 <0.001
Indwelling central line 3.33 1.88–5.92 <0.001
Ischemic stroke or palsy within 30 days 2.52 1.20–5.31 0.015
Bed rest >3 days 2.35 1.41–3.91 0.001
Hospital stay >15 days 2.26 1.36–3.76 0.002
Prior DVT 2.06 1.35–3.16 0.001
Prior PE 1.82 1.10–3.01 0.019
Chemotherapy within 6 months 0.53 0.32–0.88 0.014
Ongoing chemotherapy 0.51 0.31–0.85 0.010
Outpatient at the time of VTE diagnosis 0.31 0.18–0.53 <0.001
OR, odds ratio; CI, confidence interval; ICU, intensive care unit; DVT, deep
vein thrombosis; PE, pulmonary embolism; VTE, venous
thromboembolism.
Table 3. Independent clinical predictors of prophylaxis in patients with
cancer
Predictor OR 95% CI P
ICU admission 7.02 2.38–20.68 <0.001
Prior DVT 3.48 2.14–5.64 <0.001
Surgery within 30 days 2.43 1.19–4.99 0.015
Bed rest >3 days 2.02 1.08–3.79 0.028
Outpatient at the time of VTE diagnosis 0.38 0.19–0.76 0.006
OR, odds ratio; CI, confidence interval; ICU, intensive care unit; DVT, deep
vein thrombosis; VTE, venous thromboembolism.
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to improve prophylaxis in cancer patients. Several quality
improvement activities, such as electronic or human alerts [30],
continuing medical education [31], hospital prophylaxis
guidelines, or VTE risk assessment models may improve
prophylaxis and should be implemented systematically in
institutions who care for cancer patients.
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